Market Research Logo

Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021

Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021

About Pulmonary Arterial Hypertension (PAH) Drugs

PAH in the arteries, which carry blood from the heart to the lungs, occurs when blood vessels become narrow, making blood flow difficult.

Technavio’s analysts forecast the global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global pulmonary arterial hypertension drugs market for 2017-2021. To calculate the market size, the report considers the MoA and the RoA.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Pulmonary Arterial Hypertension Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Actelion Pharmaceuticals
  • DAIICHI SANKYO
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics
Other prominent vendors
  • AADi
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Asklepion Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Berlin Cures
  • BIAL
  • DEKA Research & Development
  • Dong- A ST
  • Eiger BioPharmaceuticals
  • Gilead Sciences
  • Lung Biotechnology
  • Merck
  • Northern Therapeutics
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Radikal Therapeutics
  • Reata Pharmaceuticals
  • SteadyMed Therapeutics
  • Velo Bio
Market driver
  • New disease-modifying therapies
  • For a full, detailed list, view our report
Market challenge
  • Patent expiries of major drugs
  • For a full, detailed list, view our report
Market trend
  • Increased focus on combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Pulmonary Arterial Hypertension Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global pulmonary arterial hypertension drugs market: Actelion Pharmaceuticals, DAIICHI SANKYO, GlaxoSmithKline, Novartis, and United Therapeutics.

Other Prominent Vendors in the market are: AADi, Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, Asklepion Pharmaceuticals, AstraZeneca, Bayer Healthcare, Berlin Cures, BIAL, DEKA Research & Development, Dong- A ST, Eiger BioPharmaceuticals, Gilead Sciences, Lung Biotechnology, Merck, Northern Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Radikal Therapeutics, Reata Pharmaceuticals, SteadyMed Therapeutics, and Velo Bio.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increased focus on combination therapies. The PAH treatment is shifting toward the use of combination therapies that employ two or more drugs. A combination therapy with separate agents or a fixed dose of combination pill offers the maximum potential to lower blood pressure. The treatment is also aimed at targeting various disease mechanisms that may result in better outcome.”

According to the report, one of the major drivers for this market is new disease-modifying therapies. Many new agents in the market are expected to show promising results in terms of efficacy as they target the receptors involved in the progression of PAH. For instance, OPSUMIT launched in 2013 in the US is an ERA, which mediates vasoconstriction, hypertrophy, and inflammation. The drug prevents the binding of endothelin (ET-1) to both endothelin receptors, ET-A and ET-B, resulting in decreased hypertension.

Further, the report states that one of the major factors hindering the growth of this market is patent expiries of major drugs. Patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in the sale of the drug. The introduction of low-cost generics, as a consequence to patent expiries, results in the rapid sales decline of the branded drugs, leading to reduced value for the overall market.

Companies Mentioned

Actelion Pharmaceuticals, DAIICHI SANKYO, GlaxoSmithKline, Novartis, United Therapeutics, AADi, Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, Asklepion Pharmaceuticals, AstraZeneca, Bayer Healthcare, Berlin Cures, BIAL, DEKA Research & Development, Dong- A ST, Eiger BioPharmaceuticals, Gilead Sciences, Lung Biotechnology, Merck, Northern Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Radikal Therapeutics, Reata Pharmaceuticals, SteadyMed Therapeutics, and Velo Bio.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • An overview of PAH
    • Table Categorization of PAH
  • Pipeline analysis
    • Table Pipeline overview
    • Table Pipeline landscape
  • Market landscape
    • Market overview
      • Table Global PAH drugs market snapshot
      • Table Global PAH drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis of global PAH market 2016
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by route of administration (RoA)
    • Table Market segmentation by RoA
    • Oral administration
    • Injectables
    • Inhalation
      • Table Global PAH drugs market segmentation by RoA 2016
  • Market segmentation by mechanism of action (MoA)
    • Table Global PAH drugs market segmentation by MoA
    • ERAs
      • Table Global ERAs market 2016-2021 ($ millions)
    • Prostacyclin analogs
      • Table Global prostacyclin analogs market 2016-2021 ($ millions)
    • PDE inhibitors
      • Table Global PDE inhibitors market 2016-2021 ($ millions)
    • sGC stimulators
      • Table Global PAH sGC stimulators market 2016-2021 ($ million)
  • Geographical segmentation
    • Table Geographical segmentation of PAH drugs market
    • Table PAH drugs market revenue by geography 2016-2021 (%)
    • PAH market in Americas
      • Table Market scenario in Americas
      • Table PAH drugs market in Americas 2016-2021 ($ millions)
    • PAH market in EMEA
      • Table Market scenario in EMEA
      • Table PAH drugs market in EMEA 2016-2021 ($ millions)
    • PAH market in APAC
      • Table Market scenario in APAC
      • Table PAH drugs market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Impact of drivers on key customer segments
      • Table Impact of drivers
    • Market challenges
    • Impact of challenges on key customer segments
      • Table Impact of challenges
  • Market trends
    • Increased focus on combination therapies
    • Increase in awareness
    • Intense competition among vendors
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global PAH drugs market 2016
      • Table Competitive analysis of global PAH drugs market 2016
  • Key vendor analysis
    • Actelion Pharmaceuticals
      • Table Actelion Pharmaceuticals: Key highlights
      • Table Actelion Pharmaceuticals: Strength assessment
      • Table Actelion Pharmaceuticals: Strategy assessment
      • Table Actelion Pharmaceuticals: Opportunity assessment
    • DAIICHI SANKYO
      • Table DAIICHI SANKYO: Key highlights
      • Table DAIICHI SANKYO: Strength assessment
      • Table DAIICHI SANKYO: Strategy assessment
      • Table DAIICHI SANKYO: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • United Therapeutics
      • Table United Therapeutics: Key highlights
      • Table United Therapeutics: Strength assessment
      • Table United Therapeutics: Strategy assessment
      • Table United Therapeutics: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report